Clinical data from OBX-115, a tumor-infiltrating lymphocyte (TIL) product incorporating drug-inducible mbIL-15 (NCT05470283, NCT05086692), show modest NK cell expansion following IL-15 induction but do not report discontinuation of treatment due to toxicity (61). Here, IL15 is linked to neoplasm.